For people using weight loss injections, weight records and HbA1c describe different aspects of type 2 diabetes care. Weight records show change on the scale; HbA1c reflects average blood glucose over roughly two to three months. Neither number alone explains how well an individual treatment plan is working.

Weight Loss Injections and Type 2 Diabetes

Weight loss injections, such as those based on GLP-1 receptor agonists, have gained attention for their potential to support weight reduction and improve glycaemic control. These medications work by influencing appetite and insulin secretion, contributing to lower blood sugar levels and weight loss. However, individual responses vary, and these treatments are typically part of a comprehensive approach including dietary changes and lifestyle adjustments.

HbA1c and Weight Loss: What Does Research Say?

HbA1c is a critical marker used to assess diabetes management. HbA1c goals should be agreed with the diabetes team. NICE uses different targets depending on treatment and individual circumstances; 30 mmol/mol is not a general treatment target for adults with type 2 diabetes. Research led by experts such as Professor Roy Taylor highlights the concept of a “personal fat threshold” — the idea that each person has a limit of fat accumulation in organs like the liver before diabetes develops.

Reducing visceral fat, particularly liver fat, through weight loss can improve insulin sensitivity and potentially normalise blood glucose levels. However, not everyone achieves optimal HbA1c even after significant weight loss, possibly due to the duration of diabetes or individual metabolic differences.

Why weight loss and HbA1c may change at different rates

Personal accounts from individuals with T2D using weight loss injections report varied outcomes. Some experience significant HbA1c improvements before reaching their target weight, while others find that blood sugar control plateaus despite further weight loss. These experiences underscore the importance of personalised management and realistic expectations.

Alongside blood tests, appointments can address eating patterns, medicine tolerability and the practical support a person needs. A disappointing result is not proof of poor willpower.

Questions for a diabetes review

Ask what HbA1c target applies to you, when the next test is due, and how the clinician will interpret changes alongside medicines and symptoms. Do not change diabetes treatment to chase a number taken from another person’s account.

This is general education. Prescription medicines and research-use compounds are different categories; a research product should not replace prescribed diabetes care.

Related reading

Explore GLP-1 medicines explained, HbA1c as a clinical-trial outcome.

Sources

NICE NG28: blood glucose management — https://www.nice.org.uk/guidance/ng28/chapter/Blood-glucose-management

NHS Scotland: HbA1c targets — https://mydiabetesmyway.scot.nhs.uk/resources/internal/blood-glucose-monitoring-and-hba1c-targets/